

CUMULATIVE INDEX 1995

Volume 16

March	PNEUMONIA IN THE INTENSIVE CARE UNIT, pages 1-227
June	VENOUS THROMBOEMBOLISM, pages 229-392
September	INTERVENTIONAL PULMONOLOGY, pages 393-555
December	ASTHMA, pages 557-755

Note: Page numbers of article titles are in **boldface** type.

- Abscess(es), pulmonary, CT of, 55-57
- Acrophase, defined, 699
- Activated protein C cofactor, thrombolytic disease and, 379-380
- Adenovirus, nosocomial pneumonia in ICU due to, 126
- Adolescents, asthma in, **657-670**. See also *Asthma, childhood, older children and adolescents*.
- Adrenergic agents, for asthma in infants and children, 642-643
- β -Adrenergic agonists, for asthma, 710-711
- for asthma in infants and children, 642-643
- for asthma in older children and adolescents, 662
- asthma in older children and adolescents due to, 659
- Adult respiratory distress syndrome (ARDS), and
- barotrauma, 53-55
- diagnostic imaging of, 51-55
- and fluid balance, 53
- nosocomial pneumonia in, 16-19
- pneumonia complicating, 53, **147-153**
- in animal models, 148-150
- in human studies, 150-152
- incidence, 147
- Aerosol therapy, for asthma in infants and children, 641-642
- Age, as factor in community-acquired pneumonia in ICU, 159-160
- as factor in venous thromboembolism, 237
- β -Agonists, death from asthma due to, 717-719
- deterioration in asthma due to, control of, 719
- inhaled, for asthma, controversies related to, **715-733**
- regular versus intermittent use of, for asthma, 716-717
- Airflow resistance, 569-572
- distribution of, 570-572
- lung volume and, 570
- Airway(s), airflow resistance in, 569-572
- in asthma patients, 559
- distal, sampling of, in diagnosis of ventilator-associated pneumonia, 66-68
- hyperreactivity of, asthma and, 604
- lower, defense mechanisms of, 3-4
- described, 3-4
- proximal, sampling of, in diagnosis of ventilator-associated pneumonia, 65-66
- upper, described, 1-3
- Airway hyperresponsiveness, in asthma in children, 638-639
- Airway obstruction, assessment, 467-468
- exercise-induced, **671-682**. See also *Asthma, exercise-induced*.
- Airway stenosis, anatomic classification of, 401-403
- benign, in children, treatment, 411
- endoscopic management, **401-413**
- anesthesia in, 404
- complications, 410-411
- dilation for, 405
- future directions for, 412
- intraluminal stenting, 407
- lasers, 407-408
- mucosal sparing techniques, 407
- outcome of, predictive features for, 409
- perioperative adjuvant therapies, 409-410
- postoperative care, 405
- procedure, 404-405
- open surgical options for, 411-412
- preoperative diagnosis and evaluation, 403
- published multimodality series for, 408-409
- signs and symptoms, 403
- subglottic, described, 402
- tracheal, described, 402-403
- Airway stent(s), **465-478**
- complications, 474-475
- future developments for, 475-476
- Gianturco stent, 471, 472
- historic perspectives, 468-469
- impact on patient care, 473-474
- indications, 465-467
- metal stents, 471-473
- Neville stent, 468
- Nova stent, 470-471, 472
- Palmaz stent, 472, 473
- Schneider stent, 471, 472
- silicone stents, 469-471, 472
- T tubes, 468-471, 472
- Wallstent, 471-473
- Alcoholism, as factor in community-acquired pneumonia in ICU, 160
- Allergen(s), avoidance of, 612-613
- environmental, in asthma in older children and adolescents, 661

Allergen(s) (Continued)

- foods and additives, 609
- immunotherapy for, 613-616
- indoor, cockroaches, 607
 - dogs, 607
 - domestic cats, 607
 - environmental history of, 606
 - house dust mites, 606-607
 - rodents, 607
 - sources, 605-607
- inhalation of, and asthma, 603-620
 - asthma due to, in children, treatment, 664
 - in older children and adolescents, 658
 - molds, 608-609
 - noninhaled, 609
 - pollens, 607-608
 - sensitization to, detection of, 609-612
 - treatment, 612-616
- Alveolar (airspace) disease, 46
- Alveolar hypoventilation, 574-575
- Alveolar macrophage(s), described, 3-4
- Aminoglycosides, for *Pseudomonas aeruginosa* pneumonia, 102-103
- Amrinone, for pulmonary embolism, 333-334
- Anesthesia/anesthetics, in cryotherapy for tracheobronchial disorders, 432
 - in endoscopic management of benign airway stenosis, 404
 - in laser bronchoscopy, 420-421
 - in thoracoscopy for malignant pleural effusions, 509
- Angiography, pulmonary, in chronic thromboembolic pulmonary hypertension, 362-363
 - development of, 229
- Angioscopy, pulmonary, in chronic thromboembolic pulmonary hypertension, 363
- Antacids, pneumonia due to, in multiple trauma patients, 137-138
- Anti-inflammatory drugs, nonsteroidal (NSAIDs), asthma in older children and adolescents due to, 659
- Antibiotics, in diagnosis of community-acquired pneumonia in ICU, 167-168, 203-205
 - in endoscopic management of benign airway stenosis, 409-410
 - for pneumonia in patients with multiple trauma, 140-141
 - for *Pseudomonas aeruginosa* pneumonia, 100-104
 - for ventilator-associated pneumonia, failure to respond to, 173-193
- Anticholinergics, for asthma, 711
 - in infants and children, 647
- Anticoagulants, for acute pulmonary embolism, 230-231
 - lupus, and antiphospholipid antibody syndrome, 380-381
 - oral, in prevention of venous thromboembolism, 243
 - for Paget-Schroetter syndrome, 343-345, 347-349
 - vena cava filter devices with, 301-302
 - for venous thromboembolism, 269-280
 - heparin, 269-274. See also *Heparin*, for venous thromboembolism.
 - warfarin, 274-276
- Antiphospholipid antibody syndrome, lupus anticoagulants and, 380-381
- Antiplatelet agents, in prevention of venous thromboembolism, 243-244
- Antithrombin III deficiency, thrombolytic disease and, 377-378
- Arachidonic acid, for inflammatory response in asthma, 590
- ARDS. See *Adult respiratory distress syndrome*.
- Arm, veins of, thrombosis of, 341-351. See also *Paget-Schroetter syndrome*.
- Aspirates, endotracheal, in diagnosis of ventilator-associated pneumonia, 65-66
 - tracheal, in diagnosis of *Staphylococcus aureus* pneumonia, 115
- Aspiration, percutaneous lung needle, for diagnosis of community-acquired pneumonia in ICU, 164-165
 - pneumonia due to, in multiple trauma patients, 137-138
 - tracheal, in diagnosis of *Staphylococcus aureus* pneumonia, 115
 - transtracheal, in diagnosis of *Staphylococcus aureus* pneumonia, 115
- Aspiration pneumonia, diagnostic imaging of, 49-50
- Asthma, acute, physiologic changes in, 578-580
 - treatment, 666
 - adhesion molecules in, role of, 596-598
 - β -Agonists, for, inhaled, 715-733. See also under β -Agonists.
 - airway function in, nocturnal changes in, mechanisms of, 703-705
 - allergen-induced, 603-620
 - in children, treatment, 664
 - causes, 604
 - changes in airways in, 559
 - childhood, incidence, 657
 - infants and small children, 637-656
 - airway hyperresponsiveness in, 638-639
 - clinical presentation, 637-638
 - diagnosis, 639-640
 - differential diagnosis, 639-640
 - environmental control for, 647-649
 - long-term outcome of, 647-648
 - pathophysiology, 639
 - treatment, 640-647
 - older children and adolescents, 657-670
 - allergies and, 658
 - compliance and, 666-668
 - drugs for, 661-664
 - environmental allergen control in, 661
 - exercise and, 658-659
 - infections and, 657-658
 - irritant exposure and, 659
 - medications and, 659
 - monitoring of, 660-661
 - treatment, 660-666
 - chronic, 664-665
 - intermittent, 664
 - triggers for, 657-659
 - vocal cord dysfunction due to, 659-660
 - prevalence, 637
 - chronic severe, physiologic changes in, 576-578
 - chronobiology and chronotherapy of, 699-713
 - communication with school, 560
 - corticosteroids for, 706-709
 - controversies related to, 715-733
 - defined, 558
 - education program for, 557-565
 - assessment techniques, 562
 - content of, 558-562
 - educating providers to educate patients, 564
 - implementation of, 562-564
 - individual patient needs survey, 563
 - inhaler use, 558, 559
 - teaching methods, 562-563
 - timing of, 564
 - topics for, 558-562
 - emergency care for, indications, 560
 - eosinophils in, 586-587

- exercise-induced, 671-682
 airway cooling versus mucosal drying in, 673-674
 in children, treatment, 664
 clinical features, 675-676
 defined, 671
 diagnosis, 677-678
 historical review, 672
 hypersensitivity in, mediators of, 675
 late reactions, 676-677
 pathogenesis, 672-675
 prevalence, 671
 treatment, 678-679
 as vascular phenomenon, 674-675
 family understanding and support in, 560
 fears related to, 560
 feelings about, 560-561
 gastroesophageal reflux and, 688-693
 glucocorticoids for, new, 728
 histopathologic findings in, 584
 home peak expiratory flow rate monitoring for, 560
 inflammation and, 583-602. See also *Inflammation, in asthma.*
 mast cells in, 587-588
 misconceptions about, 560
 occupational, 621-636. See also *Occupational asthma.*
 overview of, 701-705
 physiologic diagnosis and function in, 567-581
 prevalence, 735
 pulmonologist in, requirements of, 603-620
 signs and symptoms, 558
 onset of, 560
 prevention, 560
 sinusitis and, 683-688. See also *Sinusitis, chronic, in asthma.*
 theophyllines for, 709-710
 thermally induced, 671
 treatment, 559
 controversies related to, 715-733
 evaluation, 560
 future, 735-744
 conceptual framework for, 738-740
 development of, 740-742
 patient fears concerning, 559
 written diaries in, 559
 written guidelines for, 559
 triggers of, avoidance of, 559
 virus-induced, in children, treatment, 664
 Atelectasis, diagnostic imaging of, 50-51
 Atropine, for asthma in infants and children, 647
 Axillosubclavian vein thrombosis (ASVT),
 "spontaneous," 341-351. See also *Paget-Schroetter syndrome.*
- Bacterial pneumonia, defined, 13
 Barotrauma, ARDS and, 53-55
 Beclomethasone dipropionate (BDP), for asthma in
 infants and children, 645
 Behçet's syndrome, thrombolytic disease and, 385
 Biopsy, lung, in diagnosis of *Staphylococcus aureus*
 pneumonia, 116
 open-lung, in diagnosis of ventilator-associated pneu-
 monia, 76
 Bleeding, thrombolytic therapy and, 321-328
 in deep venous thrombosis, 322-323, 325-326
 mechanism of, 321-322
 in pulmonary embolism, 323-326
 treatment, 326
 Blood cultures, in diagnosis of *Staphylococcus aureus*
 pneumonia, 115
 in diagnosis of ventilator-associated pneumonia, 64
 Bone(s), long, fracture of, as factor in venous
 thromboembolism, 238
 Brachytherapy, defined, 445
 endobronchial, 445-454
 complications, 447-448
 contraindications, 447
 dose rate in, 446-447
 history of, 445-446
 indications, 447
 at Lahey Clinic, 448-452
 patient selection, 447
 techniques, 446-447
 Bronchoalveolar lavage (BAL), in diagnosis of
 community-acquired pneumonia in ICU, 163-164
 in diagnosis of ventilator-associated pneumonia,
 73-75
 Bronchogenic carcinoma, 427-428
 death due to, 455
 photodynamic therapy for, 455-463
 diagnosis and treatment, 457-461
 Bronchopneumonia, described, 13-16
 diagnostic imaging of, 48, 50
 Bronchoprovocation testing, nonspecific, in occupational
 asthma, 627
 specific, in occupational asthma, 627-628
 Bronchoscope(s), rigid versus flexible, 417-419
 Bronchoscopy, in diagnosis of community-acquired
 pneumonia in ICU, 163-164
 in diagnosis of ventilator-associated pneumonia,
 70-76
 risks associated with, 75-76
 fiberoptic, flexible, in airway evaluation, 467-468
 in airway stenosis evaluation, 403
 ultrasound-guided, 519-534
 clinical results, 523-532
 study design, 522-523
 technique, 520-522
 historical perspective, 393-394
 laser, 415-426
 anesthesia in, 420-421
 complications, 423-424
 indications, 417
 outcome of, 421-423
 technique, 419-420
 open tube, 394-395
 rigid, 393-399
 in cryotherapy, 397
 for foreign-body removal, 396
 historical perspective, 393-394
 in infants and children, 395-396
 laser, 397-398
 specimen removal by, 397
 as stent for pediatric tracheostomy, 397
 for tracheal reconstruction, 397
 for tracheal strictures, 396
 Bronchus(i), intermedius, description, location by CT
 scan, and puncture site, 539-540
 right upper lobe, description, location by CT scan,
 and puncture site, 538-539
 strictures of, 396
 Broyles, E.N., 394
 Budesonide, for asthma in infants and children, 645
- Carbon dioxide laser(s). See *Laser(s), carbon dioxide.*
 Carina, description, location by CT scan, and puncture
 site, 537-538
 Catheter embolectomy, for pulmonary embolism,
 334-336

- Catheter-tip fragmentation, for acute pulmonary embolism, 231-232
- Catheterization, right-heart, in chronic thromboembolic pulmonary hypertension, 362
- Cats, allergy due to, 607
- Ceftazidime, for *Pseudomonas aeruginosa* pneumonia, 102
- Chemotherapy, cryotherapy with, for tracheobronchial disorders, 436
- hypercoagulable states due to, 384
- Chest, flail, pneumonia due to, in multiple trauma patients, 138
- injury to, pneumonia due to, in multiple trauma patients, 138
- Children, asthma in, 637-656, 657-670. See also *Asthma, childhood, infants and small children; Asthma, childhood, older children and adolescents.*
- benign airway stenosis in, treatment, 411
- rigid bronchoscopy in, 395-396
- tracheostomy in, stent for, 397
- Cholinergic tone, in asthma, 703-704
- Chronobiology, 699
- Chronotherapy, in asthma, 705-711
- and chronotoxicity, of asthma, 700-701
- Chronotoxicity, chronotherapy and, 700-701
- Chymase, for inflammatory response in asthma, 590
- Ciprofloxacin, for *Pseudomonas aeruginosa* pneumonia, 103
- Clavulanate, for *Pseudomonas aeruginosa* pneumonia, 102
- Cockroaches, allergy due to, 607
- Computed tomography (CT), of empyema, 55-57
- of pulmonary abscess, 55-57
- Computerized impedance plethysmography (CIP), in diagnosis of deep venous thrombosis, 255
- Congestive heart failure, as factor in venous thromboembolism, 239
- venous thromboembolism prophylaxis in patients with, 246
- Contraceptives, oral, as factor in venous thromboembolism, 240-241
- Corticosteroid(s), for asthma, 705-709
- controversies related to, 715-733
- in infants and children, 644-645
- in older children and adolescents, 663
- in endoscopic management of benign airway stenosis, 409-410
- inhaled, adverse effects, 646-647
- for asthma, 721-722
- benefits of, 724-726
- dose dependence of, for asthma, 722-724
- toxicity of, 726-728
- Cromolyn, for asthma, in infants and children, 643-644
- in older children and adolescents, 663
- Cryobiology, defined, 428
- Cryogen(s), 429-430
- Cryotherapy. See also *Freezing.*
- chemotherapy with, for tracheobronchial disorders, 436
- described, 427
- for foreign-body removal, 441
- immune system effects of, 441-442
- radiotherapy with, for tracheobronchial disorders, 436, 440
- rigid bronchoscope in, 397
- of tissue, 428
- for tracheobronchial disorders, 427-443
- anesthesia for, 432
- benign lesions, 440
- cryogens in, 429-430
- efficacy studies, 433-434
- electrical methods, 433
- equipment, 430-431
- history of, 427
- malignant lesions, 435
- monitoring of, 433
- new approaches, 436
- patient selection, 431-432
- technique, 432-433
- thermal methods, 433
- volume measurements, 433
- for tracheobronchial stenosis following lung transplantation, 440-441
- CT. See *Computed tomography.*
- Cytokine(s), for inflammatory response in asthma, 591-592
- and the lung, 4-9
- Cytokine release, in sinusitis-induced asthma, 685-686
- Czermak, J.N., 393
- Dead space-like ventilation, 574
- Dehydration, cell damage due to, 428
- Dexamethasone, for asthma, 709
- in infants and children, 644
- in endoscopic management of benign airway stenosis, 410
- Dextran, in prevention of venous thromboembolism, 243
- Digestive tract, decontamination of, for prevention of pneumonia in multiple trauma patients, 142-143
- Dilation, for benign airway stenosis, 405
- Dobutamine, for pulmonary embolism, 333
- Dogs, allergy due to, 607
- Dopamine, for pulmonary embolism, 332, 333
- Drainage procedures, for *Pseudomonas aeruginosa* pneumonia, 104
- Drug delivery systems, for asthma in older children and adolescents, 661-662
- Dust mites, allergy due to, 606-607
- Dysfibrinogenemia(s), thrombolytic disease and, 380
- Dyspnea, in chronic thromboembolic pulmonary hypertension, 356
- Echocardiography, in chronic thromboembolic pulmonary hypertension, 359-360
- Education, asthma, 557-565. See also *Asthma, education program for.*
- Embolectomy, catheter, for pulmonary embolism, 334-336
- surgical, for pulmonary embolism, 336-337
- Embolism, pulmonary. See *Pulmonary embolism.*
- Empyema, CT of, 55-57
- thoracoscopy in, 493
- Endobronchial brachytherapy, 445-454. See also *Brachytherapy, endobronchial.*
- Endotracheal aspirates, in diagnosis of ventilator-associated pneumonia, 65-66
- Enoxaparin, following hip replacement, 286-287
- Enzyme(s), for inflammatory response in asthma, 590
- Eosinophil(s), in asthma, 586-587
- Epidemic infections, 212
- Epinephrine, for pulmonary embolism, 333
- Estrogen, hypercoagulable states due to, 384
- Exercise, airway obstruction due to, 671-682. See also *Asthma, exercise-induced.*
- asthma due to, in children, treatment, 658-659, 664
- Extrapulmonary infection, antibiotic failure due to, 183
- Extremity(ies), venous thrombosis of, thrombolytic therapy for, 319

- Fever, in ventilator-associated pneumonia patients,
infectious causes, 81-84
noninfectious causes, 84-86
- Fibrinolysis, inherited, abnormalities of, thrombolytic
disease and, 380
- Fibrinolytic therapy, for Paget-Schroetter syndrome,
343-345, 347-349
- Flail chest, pneumonia due to, in multiple trauma
patients, 138
- Fluid balance, ARDS and, 53
- Flunisolide, for asthma in infants and children, 645
- Fluticasone propionate, for asthma in infants and
children, 645
- Food, allergy due to, 609-612
- Food additives, allergy due to, 609
- Foreign bodies, removal of, cryotherapy for, 441
- rigid bronchoscopy for, 396
- Fracture(s), hip, in prevention of venous
thromboembolism, 246
- Freezing, biochemical effects of, 429
mechanisms of cellular, 428-429
vascular changes with, 429
- Garcia, M., 393
- Gas exchange, described, 574-575
evaluation of, in chronic thromboembolic pulmonary
hypertension, 358-359
- Gastroesophageal reflux, in asthma, 688-693, 705
induction of, 690
measurement of, 689
pathophysiology, 688-689
prevalence, 689-690
treatment, 690-693
defined, 688-689
- Gastrointestinal tract, role in prevention of ventilator-
associated pneumonia, 199-202
- Gianturco stent, 471, 472
- Glucocorticoid(s), new, for asthma, 728
- Glucocorticosteroid(s), for asthma in older children and
adolescents, 663
- Günther filter, for interruption of venous return, 297
- Graduated elastic compression stockings (GCS), in
prevention of venous thromboembolism, 244
- Greenfield filter, for interruption of venous return,
296-298
- Hematoporphyrin derivative (HpD), for bronchogenic
carcinoma, 455-463
- Hemoglobinuria, paroxysmal nocturnal, thrombolytic
disease and, 382-383
- Hemostasis, overview, 376
- Heparin, for acute pulmonary embolism, 231
for deep venous thrombosis, 322-323
hypercoagulable states due to, 384
low-molecular-weight (LMWH), for venous thrombo-
embolism, 281-294
adverse effects, 283
anticoagulant effects, 282-283
clinical trials, 283-290
pharmacokinetics, 282-283
mechanism of action of, 270
pharmacology of, 270
in prevention of venous thromboembolism, 242-243,
244
for pulmonary embolism, 323-325
for venous thromboembolism, 269-274
laboratory monitoring, 270
quality assurance of, 272-274
therapeutic range, 270, 271-272
variability of APTT results, 271
- Herpes simplex virus (HSV), nosocomial pneumonia in
ICU due to, 126-127
- Hip, fracture of, as factor in venous thromboembolism,
238
venous thromboembolism prophylaxis in patients
with, 246
- Hip replacement, LMWH following, 286-288
venous thromboembolism prophylaxis in patients
undergoing, 245
- Histamine, for inflammatory response in asthma, 590
plasma, in asthma, 705
- Histamine, blockers, pneumonia due to, in multiple
trauma patients, 137-138
- Holinger, P.H., 394
- Homocystinuria, thrombolytic disease and, 383
- Hopkins, H.H., 394
- Humoral immune system, role of, 2-3
- Hypercoagulable state(s), activated protein C cofactor,
379-380
antithrombin III deficiency, 377-378
assessment of patients with, 376-377
Behçet's syndrome, 385
defined, 375
dysfibrinogenemias, 380
evaluation, 375-387
homocystinuria, 383
inflammatory bowel disease, 385
inherited abnormalities of fibrinolysis, 380
malignancy, 381-382
myeloproliferative syndromes, 382
nephrotic syndrome, 384
paroxysmal nocturnal hemoglobinuria, 382-383
pregnancy, 383-384
primary, 377-380
protein C deficiency, 378-379
protein S deficiency, 379
secondary, 380-385
stasis, 385
therapy-related, 384
- Hyperresponsiveness, airway, in asthma in children,
638-639
- Hypersensitivity, in exercise-induced asthma, mediators
of, 675
- Hypertension, pulmonary, chronic thromboembolic,
353-374
clinical presentation, 356-357
diagnostic evaluation, 357-363
mortality due to, 353
natural history, 354-356
treatment, 363-368
- Hypoventilation, alveolar, 574-575
- Ice crystals, mechanical damage from, 429
- ICU. See *Intensive care unit.*
- Ikeda, S., 394
- Imaging, for pneumonia in ICU patients, 45-59. See also
specific techniques, e.g., *Ultrasound.*
- Imipenem, for *Pseudomonas aeruginosa* pneumonia, 102
- Immobility, as factor in venous thromboembolism, 240
- Immobilization, pneumonia due to, in multiple trauma
patients, 138
- Immune system, cryotherapy effects on, 441-442
humoral, role of, 2-3
- Immunocompromise, as factor in community-acquired
pneumonia in ICU, 161

- Immunomodulation, for diagnosis of community-acquired pneumonia in ICU, 205
- Immunotherapy, allergen, 613-616
- for *Pseudomonas aeruginosa* pneumonia, 104-105
- Impedance plethysmography, computerized (CIP), in diagnosis of deep venous thrombosis, 255
- in diagnosis of deep venous thrombosis, 254-255
- Infant(s), asthma in, 637-656. See also *Asthma, childhood*.
- rigid bronchoscopy in, 395-396
- tracheostomy in, stent for, 397
- Infection(s). See also specific types.
- asthma due to, in children, treatment, 664
- in older children and adolescents, 657-658
- epidemic, 212
- extrapulmonary, antibiotic failure due to, 183
- nosocomial, described, 209-210
- occult, scanning for, 58
- Inferior vena cava filter, in patients with venous thromboembolism, indications, 247
- Inflammation, in asthma, 583-602
- adhesion molecules in, 596-598
- cellular migration in, 594-596
- late phase response as inflammatory model, 585-586
- leukocyte adhesion in, 592-594
- lymphocytes in, 588-589
- mechanism of, 585
- mediators of, 589-592
- overview of, 584-585
- Inflammatory bowel disease, thrombolytic disease and, 385
- Inflammatory cells, in asthma, 705
- Influenza virus, nosocomial pneumonia in ICU due to, 124-125
- Inhalation delivery systems, for asthma in infants and children, 641-642
- Inhaler use checklist, 558, 559
- Intensive care unit (ICU), community-acquired pneumonia in, 155-171. See also *Pneumonia, community-acquired, in ICU*.
- epidemic nosocomial pneumonia in, 209-223
- nosocomial pneumonia in, epidemiology, 29-44
- viral, 121-133. See also *Nosocomial pneumonia, viral, in ICU*.
- Intermittent pneumatic compression of the legs (IPC), in prevention of venous thromboembolism, 244
- Interstitial pneumonia, diagnostic imaging of, 48-49, 51
- Intraluminal stenting, for benign airway stenosis, 407
- Intubation, avoidance of, in prevention of pneumonia in multiple trauma patients, 142
- pneumonia due to, in multiple trauma patients, 137
- Ipratropium bromide, for asthma in infants and children, 647
- Irritant(s), exposure to, asthma in older children and adolescents due to, 659
- Isoproterenol, for pulmonary embolism, 333
- Jackson, C., 393-394
- Knee replacement, venous thromboembolism prophylaxis in patients undergoing, 245-246
- Lacerations, pneumonia due to, in multiple trauma patients, 138
- β -Lactams, for *Pseudomonas aeruginosa* pneumonia, 102
- Lahey Clinic, endobronchial therapy at, 448-452
- Laryngology, father of, 393
- Laser(s), for benign airway stenosis, 407-408
- carbon dioxide, history of, 415-416
- in rigid bronchoscopy, 397-398
- as light sources, 416-417
- Nd:YAG, for benign airway stenosis, 407-408
- described, 416-417
- in rigid bronchoscopy, 397-398
- in rigid bronchoscopy, 397-398
- Laser bronchoscopy, 415-426. See also *Bronchoscopy, laser; Laser(s)*.
- Left upper lobe spur, description, location by CT scan, and puncture site, 540
- Leg(s), intermittent pneumatic compression of (IPC), in prevention of venous thromboembolism, 244
- Lesion(s), pathologic, in nosocomial pneumonia, 21-27
- Leukocyte(s), adhesion of, in asthma, 592-594
- Leukotriene(s), for inflammatory response in asthma, 590
- LMWH. See *Heparin, low-molecular-weight*.
- Lobar pattern pneumonia, diagnostic imaging of, 47, 49, 50
- Long-bone, fracture of, as factor in venous thromboembolism, 238
- LTB₄, for inflammatory response in asthma, 590
- LTC₄, for inflammatory response in asthma, 590
- LTD₄, for inflammatory response in asthma, 590
- LTE₄, for inflammatory response in asthma, 590
- Lung(s), biopsy of, in *Staphylococcus aureus* pneumonia, 116
- techniques, 484-485
- thoracoscopic-guided, in diffuse pulmonary disease, 492-493
- cancer of, staging and diagnosis of, nodal stations, 535-541
- percutaneous needle aspiration for, 535-552
- transbronchial needle aspiration for, 535-552
- cytokines and, 4-9
- described, 484
- diseases of, diffuse, thoracoscopy in, 492-493
- thoracoscopy in, 487-496
- function of, in asthma, 567-581
- gas exchange in, 574-575
- human, 13-19
- mechanical properties of, 567-574
- nodules of, diagnosis, 547-550
- Lung capacity, 567-568
- Lung elastic recoil, 569
- Lung transplantation, tracheobronchial stenosis following, cryotherapy for, 440-441
- Lung volume, 567-569
- and airflow resistance, 570
- Lupus anticoagulants, and antiphospholipid antibody syndrome, 380-381
- Lymphocyte(s), in asthmatic inflammation, 588-589
- Macrophage(s), alveolar, described, 3-4
- Magnetic resonance imaging (MRI), in acute pulmonary embolism diagnosis, 232
- in deep venous thrombosis diagnosis, 261-264
- accuracy of, 263-264
- technique and interpretation, 261-263
- Malignancy, as factor in venous thromboembolism, 239
- thrombolytic disease and, 381-382
- Mast cells, in asthma, 587-588
- Maximal expiratory flow rates, 572-574
- Maximal inspiratory flow rates, 572

- Measles virus, nosocomial pneumonia in ICU due to, 127-128
- Mesothelioma(s), malignant, 515-516
 thoracoscopy in, 491
- Metal stents, 471-473
- Methylprednisolone, for asthma, 709
 in infants and children, 644-645
- Mobin-Uddin umbrella device, for interruption of venous return, 295-296
- Molds, allergy due to, 608-609
- Multiple trauma, as factor in venous thromboembolism, 239
 venous thromboembolism prophylaxis in patients with, 246
- Myeloproliferative syndromes, thrombolytic disease and, 382
- Myocardial infarction, as factor in venous thromboembolism, 239
 venous thromboembolism prophylaxis in patients with, 246
- Nasogastric tubes, pneumonia due to, 138
- Nasopharynx, described, 1
- National Asthma Education Program (NAEP), 557. See also *Asthma, education program for*.
 goals of therapy, 558
 implementation of, 562-564
 topics to be included in, 558-562
- Nd:YAG laser. See *Laser(s), Nd:YAG*.
- Nedocromil, for asthma, in infants and children, 644
 in older children and adolescents, 663
- Nephrotic syndrome, thrombolytic disease and, 384
- Neurohormonal changes, in asthma, 703
- Neurosurgical procedures, venous thromboembolism prophylaxis in patients undergoing, 246
- Neurotrauma, pneumonia due to, in multiple trauma patients, 137
- Neville stent, 468
- Nonresolving pneumonia, 186-187
- Norepinephrine, for pulmonary embolism, 332-333
- Nosocomial infections, described, 209-210
- Nosocomial pneumonia, acquisition of, 20
 in ARDS, 16-19
 epidemic, in ICU, 209-223
 investigation of, 215-221
 modes and sources of transmission of, 212-215
 epidemiology, 210
 features of, 16-17
 in ICU patients, cost factors, 31-32
 described, 121
 epidemiology, 29-44, 210
 historical aspects, 29-30
 incidence, 30, 31
 modes of inoculation for, 33-36
 morbidity related to, 31-32
 mortality related to, 30-31
 pathogens of, 32
 reservoirs for, 33
 risk factors for, 36-37
 pathogenesis, 19-21, 210-212
 pathologic lesions in, 21-27
 pathology of, 13-28
 surveillance of, 210
 viral, and host defenses, 122-123
 in ICU, 121-133
 diagnosis, 128-129
 pathogens of, 123-128
 prevention of spread, 130
 treatment, 129-130
 when to suspect, 123
- Nova stent, 470-471, 472
- Nutritional support, role in prevention of ventilator-associated pneumonia, 202-203
- Obesity, as factor in venous thromboembolism, 239
- Occupational asthma, 621-636
 causes, 622-625
 defined, 621
 diagnosis, exposure assessment, 626
 immunologic assessment, 628-629
 physiologic assessment, 626-628
 reasons for, 621-622
 tools in, 622-629
 immunologically mediated, prevention, 630-631
 incidence, 621
 irritant-induced, prevention, 630
 management, 629-630
 patient history in, 622-626
 prevention, 630-631
- Open-lung biopsy, in diagnosis of ventilator-associated pneumonia, 76
- Oral contraceptives, as factor in venous thromboembolism, 240-241
- Organ dysfunction, antibiotic failure due to, 184-185
- Oropharynx, described, 1
- Orthopedic surgery, LMWH following, clinical trials, 286-288
- Oscillation, postural, continuous, for prevention of pneumonia in multiple trauma patients, 141
- Paget-Schroetter syndrome, 341-345
 catheter-induced, asymptomatic, 349-350
 symptomatic, 345-349
 causes, 341-342
 clinical presentation, 342
 patient evaluation, 342-343
 treatment, 343-345, 347-349
- Pain, control of, for prevention of pneumonia in multiple trauma patients, 142
- Palmaz stent, 472, 473
- Parainfluenza viruses, nosocomial pneumonia in ICU due to, 128
- Paroxysmal nocturnal hemoglobinuria, thrombolytic disease and, 382-383
- Peak expiratory flow rate monitoring, in occupational asthma, 627
- Pelvis, fracture of, as factor in venous thromboembolism, 238
- Percutaneous lung needle aspiration, for diagnosis of community-acquired pneumonia in ICU, 164-165
- Percutaneous needle aspiration (PCNA), in lung cancer staging and diagnosis, 535-552
 instrumentation, 541-542
 technique, 542-547
 transbronchial needle aspiration versus, 550-551
- Perfusion, venous admixture-like, 574
- Photodynamic therapy, for bronchogenic carcinoma, 455-463
 described, 455
 history of, 455
 mechanism of action of, 456-457
- Photosensitizers, porphyrin-based, for bronchogenic carcinoma, 455-463
- Piperacillin, for *Pseudomonas aeruginosa* pneumonia, 102

- Plasma cyclic adenosine monophosphate (CAMP), in asthma, 704-705
- Plasma histamine, in asthma, 705
- Platelet-activating factors, for inflammatory response in asthma, 591
- Plethysmography, impedance, computerized (CIP), in diagnosis of deep venous thrombosis, 255
- Pleural biopsy, 510-512
- Pleural cavity, thoracoscopic inspection of, 510
- Pleural diseases, thoracoscopy in, 487-496
- Pleural effusions, biopsy of, 510-512
- malignant, diagnosis, 507-508
- thoracoscopy, 505-518. See also *Thoracoscopy, for malignant pleural effusions*.
- thoracoscopy in, 489-490
- tuberculous, thoracoscopy in, 491-492
- Pleural fluid analysis, for diagnosis of community-acquired pneumonia in ICU, 163
- Pleural malignancies, metastatic, thoracoscopy in, 489-490
- Pleural space, anatomy and physiology of, 505-507
- thoracoscopic access to, 509-510
- Pleurectomy, 512-513
- Pleurodesis, 512
- in spontaneous pneumothorax, 500-502
- talc, 485, 513-515
- Pneumatoceles, pneumonia due to, in multiple trauma patients, 138
- Pneumonia, in ARDS, 53, 147-153. See also *Adult respiratory distress syndrome (ARDS), pneumonia complicating*.
- aspiration, diagnostic imaging of, 49-50
- bacterial, defined, 13
- community-acquired, in ICU, 155-171
- age and, 159-160
- alcoholism and, 160
- diagnosis, 162-165
- host factors, 159-161
- immunocompromise and, 161
- management, 165-168
- microbiologic and clinical characteristics, 155-159
- mortality due to, 161-162
- prognostic factors, 161-162
- defined, 61
- in ICU. See also *Nosocomial pneumonia*.
- ARDS and, 51-55
- atelectasis in, 50-51
- diagnostic imaging of, 45-59. See also *Imaging, for pneumonia in ICU patients*.
- pathophysiology, 1-12
- types of, diagnostic imaging of, 46-50
- interstitial, diagnostic imaging of, 48-49, 51
- lobar pattern disease, diagnostic imaging of, 47, 49, 50
- nonresolving, 186-187
- nosocomial. See *Nosocomial pneumonia*.
- pathogenesis, 20-21
- in patients with multiple trauma, 135-146
- diagnosis, 138-139
- epidemiology, 135-136
- microbiology of, 139-140
- prevention, 141-143
- risk factors for, 136-138
- treatment, 140-141
- peribronchial, 16-17
- Staphylococcus aureus* infection and, 111-120. See also *Staphylococcus aureus pneumonia*.
- superinfection, antibiotic failure due to, 182-183
- ventilator-associated, 61-93
- antibiotics for, failure to respond to, 173-193
- causes, 178-185
- patterns of, 185-187
- response to, 188-190
- diagnosis, 61-80
- approach to, 87-89
- bronchoscopic techniques, 70-76
- clinical criteria for, 61-63
- factors affecting results, 76-79
- invasive procedures, 68-76
- noninvasive modalities, 64-68
- principles for, 63-64
- differential diagnosis, 80-87
- local and systemic effects, 176
- management, 79-80
- mortality from, 173-175
- prevention, 195-208
- antibiotics in, 203-205
- gastrointestinal tract in, 199-202
- immunomodulation in, 205
- infection control, 195-197
- nutritional support in, 202-203
- respiratory therapy equipment and endotracheal tubes in, 197-198
- tracheobronchial secretion mobilization, 198-199
- Pseudomonas* infection and, 95-109. See also *Pseudomonas aeruginosa pneumonia*.
- Pneumothorax, casual lesions of, 497-500
- spontaneous, pleurodesis in, 500-502
- thoracoscopy in, 497-503. See also *Thoracoscopy, in spontaneous pneumothorax*.
- Pollens, allergy due to, 607-608
- Porphyriin compounds, for bronchogenic carcinoma, 455-463
- Postnasal drainage, in sinusitis-induced asthma, 685
- Postural oscillation, continuous, in prevention of pneumonia in multiple trauma patients, 141
- Prednisone, for asthma, 706-709
- Pregnancy, as factor in venous thromboembolism, 240
- thrombolytic disease and, 383-384
- Prostaglandin(s), for inflammatory response in asthma, 590
- Prosthesis(es), tracheobronchial, 465-478. See also *Airway stent(s)*.
- Protected specimen sampling, in diagnosis of *Staphylococcus aureus* pneumonia, 115-116
- in diagnosis of ventilator-associated pneumonia, 70-73
- Protein C deficiency, thrombolytic disease and, 378-379
- Protein S deficiency, thrombolytic disease and, 379
- Pseudomonas aeruginosa* pneumonia, 95-109
- bacteriology of, 95-96
- clinical manifestations, 99
- pathogenesis, 96-98
- pathology of, 98-99
- prevention, 105
- treatment, 99-105
- Pseudomonas* infection, ventilator-associated pneumonia due to, 95-109. See also *Pseudomonas aeruginosa pneumonia*.
- Puerperium, as factor in venous thromboembolism, 240
- Pulmonary. See also under *Lung(s)*.
- Pulmonary abscess, CT of, 55-57
- Pulmonary contusion, pneumonia due to, in multiple trauma patients, 138
- Pulmonary embolism, acute, 229-233
- collaborative investigations in, 230
- diagnosis, 229-230
- laboratory tests, 230
- neural networks in, 230

- radionuclide imaging, 229-230
 - management, 230-232
- bleeding rates in, 325-326
- cause, 295
- incidence, 295, 354
- management, thrombolytic therapy in, 307-320, 323-325. See also *Thrombolytic therapy, in venous thromboembolism*.
- massive, 329-340
 - diagnosis, 330-331
 - mortality due to, 329
 - pathophysiology, 329-330
 - treatment, 331-337
 - amrinone, 333-334
 - catheter embolectomy, 334-336
 - dobutamine, 333
 - dopamine, 332, 333
 - epinephrine, 333
 - hemodynamic support, 331-334
 - inferior vena caval filter placement, 337
 - isoproterenol, 333
 - norepinephrine, 332-333
 - surgical embolectomy, 336-337
 - thrombolytic therapy, 334
 - mortality due to, prevalence, 235, 253, 295, 354
 - prevention, vena cava filter devices in, 298-299
- Pulmonary function testing, in occupational asthma, 626-628
- Pulmonary nodules, diagnosis, 547-550
- Pulmonologists, allergy knowledge of, 603-620
- Radiographic densities, in ventilator-associated pneumonia patients, causes, 86
- Radiography, chest, in chronic thromboembolic pulmonary hypertension, 357-358
- Radionuclide imaging, in acute pulmonary embolism diagnosis, 229-230
- Radionuclide venography, in deep venous thrombosis diagnosis, 264
- Radiotherapy, cryotherapy with, for tracheobronchial disorders, 436, 440
- Recombinant tissue plasminogen activator (rt-PA), for deep venous thrombosis, 322-323
 - for pulmonary embolism, 323-325
- Respiratory heat exchange, exercise-induced asthma due to, 672-673
- Respiratory syncytial virus (RSV), nosocomial pneumonia in ICU due to, 125-126
- Respiratory tract, colonization of, in nosocomial pneumonia, 19-20
 - lower, host defense mechanisms of, 5
 - upper, mechanisms of, 2
- Rodents, allergy due to, 607
- Salmeterol, safety and efficacy of, 719-721
- Schneider stent, 471, 472
- Scintigraphy, in acute pulmonary embolism diagnosis, 232
 - thrombus-avid, in deep venous thrombosis diagnosis, 264
- Selective digestive decontamination, in diagnosis of community-acquired pneumonia in ICU, 203-205
- Silicone stent(s), 469-471, 472
- Simon nitinol filter, for interruption of venous return, 297
- Sinobronchial reflex, in sinusitis-induced asthma, 685
- Sinusitis, chronic, in asthma, 683-688
 - development of, 684-685
 - infection associated with, 684
 - mechanisms for, 685-687
 - defined, 683
 - microbiology and pathology, 683-688
 - treatment, 687-688
- Specimen(s), removal of, rigid bronchoscopy for, 397
- Spinal cord injury, as factor in venous thromboembolism, 238
 - venous thromboembolism prophylaxis in patients with, 246
- Spontaneous pneumothorax, pleurodesis in, 500-502
 - thoracoscopy in, 497-503. See also *Thoracoscopy, in spontaneous pneumothorax*.
- Sputum analysis, in diagnosis of community-acquired pneumonia in ICU, 162-163
 - in diagnosis of *Staphylococcus aureus* pneumonia, 115
- Staphylococcus aureus*, microbial characteristics, 111
- Staphylococcus aureus* pneumonia, 111-120
 - clinical manifestations, 113-114
 - diagnosis, 114-116
 - epidemiology, 111-113
 - pathogenesis, 113
 - prevention, 117-118
 - treatment, 116-117
- Stasis, thrombolytic disease and, 385
- Stent(s), airway, 465-478. See also *Airway stent(s)*.
- Stockings, graduated elastic compression (GCS), in prevention of venous thromboembolism, 244
- Stomach, role in prevention of ventilator-associated pneumonia, 202-203
- Streptokinase, for deep venous thrombosis, 322-323
 - for pulmonary embolism, 323-324
- Stroke, venous thromboembolism prophylaxis in patients with, 246
- Subglottic stenosis, described, 402
- Superinfection pneumonia, antibiotic failure due to, 182-183
- Surgery, general, major, as factor in venous thromboembolism, 237-238
 - LMWH following, clinical trials, 284-286
 - orthopedic, as factor in venous thromboembolism, 238
 - LMWH following, clinical trials, 286-288
- Surgical embolectomy, for pulmonary embolism, 336-337
- T tubes, 468-471, 472
- Talc pleurodesis, 485, 513-515
- Tazobactam, for *Pseudomonas aeruginosa* pneumonia, 102
- Theophylline, for asthma, 709-710
 - in infants and children, 644
 - in older children and adolescents, 662
- Thoracoscopy, 479-486
 - chest tube care in, 485
 - complications, 485-486, 493
 - contraindications, 480, 493-494
 - described, 479
 - diagnostic, 489-493
 - in diffuse pulmonary disease, 492-493
 - double puncture technique, equipment for, 480
 - endoscopy room for, 481
 - equipment for, 480, 481
 - indications, 479-480
 - for lung biopsy, 484-485
 - for malignant mesothelioma, 491, 515-516
 - for malignant pleural effusions, 505-518

Thoracoscopy (*Continued*)

- anesthesia for, 509
- patient preparation, 508-509
- procedures, 508-513
- results, 513-516
- in staging, 513
- for metastatic pleural malignancies, 490-491
- in pleural and lung diseases, 487-496
 - historical background, 487-488
- pleural biopsy techniques, 484
- for pleural effusions, 489-490
- point of entry for, 481-482
- preprocedure for, 480
- procedure, 482-484
- single-puncture technique, equipment for, 480
- in spontaneous pneumothorax, diagnosis and treatment, 497-503
 - findings related to, 498-499
 - in stage I pneumothorax, 499
 - in stage II pneumothorax, 499
 - in stage III pneumothorax, 499
 - in stage IV pneumothorax, 499-500
- in tuberculous pleural effusions, 491-492
- video-assisted thoracic surgery versus, 488-489
- Thromboembolism, venous. See also *Thrombosis, venous*.
 - conditions involved in, 235
 - fatality rates for, 235
 - incidence, 235
 - issue on, 229-387
 - management, 281-294, 307-320, 321-328. See also *Heparin, low-molecular-weight (LMWH), for venous thromboembolism*.
 - anticoagulants, 269-280. See also *Anticoagulants, for venous thromboembolism*.
 - heparin, 269-274
 - low-molecular-weight, 281-294
 - long-term, 276-278
 - warfarin, 274-276
- prior occurrence of, as factor in venous thromboembolism, 236-237
- prophylaxis, 241-247
 - controversies related to, 246-247
 - outpatient, 246-247
 - pharmacologic, 242-244
 - in surgical patients, 245-246
- risk factors for, 235-241
 - age, 237
 - congestive heart failure, 239
 - fractures, 238
 - hematologic, 241
 - immobility, 240
 - malignancy, 239
 - multiple trauma, 239
 - myocardial infarction, 239
 - obesity, 239
 - oral contraceptives, 240-241
 - pregnancy, 240
 - prior venous thromboembolism, 236-237
 - puerperium, 240
 - spinal cord injury, 238
 - surgery, 237-238
 - varicose veins, 240
- thrombolytic therapy in, 307-320, 321-328. See also *Thrombolytic therapy, in venous thromboembolism*.
 - contraindications, 326
- vena cava filter devices in, 295-305. See also *Vena cava filter devices*.
- Thromboendarterectomy, pulmonary, for chronic thromboembolic pulmonary hypertension, 363-372
- Thrombolysis, pulmonary embolism. See *Thrombolytic therapy, in venous thromboembolism*.

- Thrombolytic therapy, for acute pulmonary embolism, 231
 - for deep venous thrombosis, 322-323
 - for pulmonary embolism, 323-325, 334
- in venous thromboembolism, 307-320, 321-328
 - alternatives and adjuncts to, 318-319
 - clinical trials, 309-316
 - complications, 321-328. See also *Pulmonary embolism; Thrombosis, deep venous*.
 - future directions in, 318
 - historical versus contemporary methods, 310
 - practicality of, 316-317
 - rationale for, 307-309
- Thrombosis, arm vein, 341-351. See also *Paget-Schroetter syndrome*.
- axillosubclavian vein (ASVT), 341-351. See also *Paget-Schroetter syndrome*.
- deep venous. See also *Thromboembolism, venous*.
 - bleeding rates in, 325-326
 - diagnosis, 253-268
 - clinician's perspective, 253-254
 - nonimaging tests, 254-255
 - insertion-site, vena cava filter devices and, 299-300
 - mortality due to, prevalence, 253
 - thrombolytic therapy in, 322-323
 - venous, deep. See *Thrombosis, deep venous*.
 - of the extremities, thrombolytic therapy for, 319
- Thrombus, formation and propagation of, components of, 375
- Tissue, cryodestruction of, 428
- Trachea, reconstruction of, rigid bronchoscopy for, 397
- strictures of, removal of, rigid bronchoscopy for, 396
- Tracheal aspiration, in diagnosis of *Staphylococcus aureus* pneumonia, 115
- Tracheal stenosis, described, 402-403
- Tracheobronchial disorders, cryotherapy for, 427-443.
 - See also *Cryotherapy, for tracheobronchial disorders*.
- Tracheobronchial stenosis, following lung transplantation, cryotherapy for, 440-441
- Tracheostomy, early, in prevention of pneumonia in multiple trauma patients, 142
- pediatric, rigid bronchoscope as stent for, 397
- Transbronchial needle aspiration (TBNA), in lung cancer staging and diagnosis, 535-552
 - instrumentation, 541-542
 - technique, 542-547
- percutaneous needle aspiration versus, 550-551
- Transplantation, lung, tracheobronchial stenosis following, cryotherapy for, 440-441
- Transtacheal aspiration, in diagnosis of *Staphylococcus aureus* pneumonia, 115
- Trauma, multiple, as factor in venous thromboembolism, 239
 - pneumonia in patients with, 135-146. See also *Pneumonia, in patients with multiple trauma*.
- venous thromboembolism prophylaxis in patients with, 246
- Triamcinolone acetonide, for asthma, 706-707
- Trypsin, for inflammatory response in asthma, 590
- Ultrasonography, in bronchoscopic evaluation, 519-534.
 - See also *Bronchoscopy, fiberoptic, ultrasound-guided*.
- in diagnosis of deep venous thrombosis, 256-261
 - accuracy of, 258-259
 - acute versus chronic assessment, 260
 - ancillary findings, 260
 - calf vein assessment, 259-260
 - criteria for, 257-258

- pitfalls of, 260
 - technique, 256-257
 - upper extremity assessment, 260-261
- in diagnosis of pneumonia in ICU patients, 58
- Ultrasound, in diagnosis of pneumonia in ICU patients, 58
- Urokinase, for pulmonary embolism, 323-325
 - acute, 231
- Varicella-zoster virus (VZV), nosocomial pneumonia in ICU due to, 127
- Varicose veins, as factor in venous thromboembolism, 240
- Vein(s), arm, thrombosis of, 341-351. See also *Paget-Schroetter syndrome*.
 - varicose, as factor in venous thromboembolism, 240
- Vena cava, inferior, obstruction of, vena cava filter devices and, 301
- Vena cava filter devices, 295-305
 - anticoagulants with, 301-302
 - complications, fatal, 299
 - filter migration, 300
 - inferior vena cava obstruction, 301
 - insertion-related, 299-300
 - nonfatal, 299-301
 - penetration into vena cava wall, 300-301
 - venous insufficiency, 301
 - evolution of, 295-298
 - Günther filter, 297
 - Greenfield filter, 296-298
 - history of, 295-296
 - indications, 295, 302-303
 - Mobin-Uddin umbrella device, 295-296
 - in prevention of pulmonary embolism, 298-299
 - selection of, 302
 - Simon nitinol filter, 297
- Vena cava interruption. See also *Vena cava filter devices*.
 - evolution of, 295-298
- Vena cava ligation, for acute pulmonary embolism, 231
- Vena caval filter devices, placement of, for pulmonary embolism, 337
- Venography, radionuclide, in diagnosis of deep venous thrombosis, 264
- Venous admixture-like perfusion, 574
- Venous thromboembolism. See *Thromboembolism, venous*.
- Venous thrombosis. See *Thrombosis, deep venous*.
- Ventilation, dead space-like, 574
- Ventilation-perfusion scanning, in chronic thromboembolic pulmonary hypertension, 359-360
- Viral infections, in ICU, 122-130
 - host defenses against, 122-123
- Vocal cords, dysfunction of, asthma and, 659-660
- Wallstent, 471-473
- Warfarin, hypercoagulable states due to, 384
 - mechanism of action of, 275
 - for Paget-Schroetter syndrome, 347-349
 - pharmacology of, 275
 - for venous thromboembolism, 274-276
- Wheezing, differential diagnosis, childhood, 639-640